Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Radiodermatitis is a group of skin reactions that occur as a result of radiation therapy. It is a significant health challenge as approximately 70% of all cancer patients receive radiation therapy and approximately 95% of them experience radiodermatitis. Patients with radiodermatitis experience redness, itchiness, pain, scaling, and weeping or crusted wounds. Importantly, radiodermatitis can impede cancer treatments. Current treatments for radiodermatitis have shown limited efficacy; thus, improving our understanding of radiodermatitis and developing novel therapies are urgent needs. In our preliminary studies, we have found that the protein Granzyme B is present at very high levels in radiodermatitis skin. We also showed that Granzyme B damages components of the skin and promotes inflammation in radiodermatitis. Our proposed project will test if Granzyme B induces the symptoms of radiodermatitis and if our newly developed medication that stops Granzyme B activity can alleviate these symptoms. Findings from this study will provide further rationale to pursue inhibitors of Granzyme B as a novel treatment option for radiodermatitis.
Layla Nabai;Megan Pawluk;Christopher Turner
Vancouver General Hospital
Health care and social assistance
University of British Columbia
Find the perfect opportunity to put your academic skills and knowledge into practice!Find Projects
The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.